Literature DB >> 20676137

MOS, aneuploidy and the ploidy cycle of cancer cells.

J Erenpreisa1, M S Cragg.   

Abstract

After DNA or spindle damage, p53-defective tumor cells undergo a complex cycle of reversible polyploidy. How this process occurs and more importantly, why, has recently become the focus of several research groups, prompting this review in which we discuss two related phenomena that accompany the reversible polyploidy of tumor cells: the induction of meiosis genes such as MOS and the decrease in genomic instability observed during the reversion from polyploidy to para-diploidy. The reversible polyploidy likely provides the means through which the balance between increased chromosome instability (CIN), driving genetic variation and decreased CIN, necessary for perpetuating these malignant clones, is maintained. These concepts are integrated with recent findings that many meiotic and self-renewal genes become activated during reversible polyploidy and lead us to the hypothesis that tumor cell immortality may be achieved through germline-like transmission.

Entities:  

Mesh:

Year:  2010        PMID: 20676137     DOI: 10.1038/onc.2010.310

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  33 in total

1.  Alternative lengthening of telomeres: recurrent cytogenetic aberrations and chromosome stability under extreme telomere dysfunction.

Authors:  Despoina Sakellariou; Maria Chiourea; Christina Raftopoulou; Sarantis Gagos
Journal:  Neoplasia       Date:  2013-11       Impact factor: 5.715

2.  The roles of telomerase in the generation of polyploidy during neoplastic cell growth.

Authors:  Agni Christodoulidou; Christina Raftopoulou; Maria Chiourea; George K Papaioannou; Hirotoshi Hoshiyama; Woodring E Wright; Jerry W Shay; Sarantis Gagos
Journal:  Neoplasia       Date:  2013-02       Impact factor: 5.715

3.  Increased asymmetric and multi-daughter cell division in mechanically confined microenvironments.

Authors:  Henry Tat Kwong Tse; Westbrook McConnell Weaver; Dino Di Carlo
Journal:  PLoS One       Date:  2012-06-25       Impact factor: 3.240

4.  Macroautophagy-aided elimination of chromatin: sorting of waste, sorting of fate?

Authors:  Jekaterina Erenpreisa; Anda Huna; Kristine Salmina; Thomas R Jackson; Mark S Cragg
Journal:  Autophagy       Date:  2012-12       Impact factor: 16.016

5.  Mos in the oocyte: how to use MAPK independently of growth factors and transcription to control meiotic divisions.

Authors:  Aude Dupré; Olivier Haccard; Catherine Jessus
Journal:  J Signal Transduct       Date:  2010-12-19

6.  Spontaneous cell fusions as a mechanism of parasexual recombination in tumour cell populations.

Authors:  Daria Miroshnychenko; Etienne Baratchart; David Basanta; Andriy Marusyk; Meghan C Ferrall-Fairbanks; Robert Vander Velde; Mark A Laurie; Marilyn M Bui; Aik Choon Tan; Philipp M Altrock
Journal:  Nat Ecol Evol       Date:  2021-01-18       Impact factor: 19.100

Review 7.  Polyploid giant cancer cell characterization: New frontiers in predicting response to chemotherapy in breast cancer.

Authors:  Geetanjali Saini; Shriya Joshi; Chakravarthy Garlapati; Hongxiao Li; Jun Kong; Jayashree Krishnamurthy; Michelle D Reid; Ritu Aneja
Journal:  Semin Cancer Biol       Date:  2021-03-22       Impact factor: 17.012

Review 8.  The "virgin birth", polyploidy, and the origin of cancer.

Authors:  Jekaterina Erenpreisa; Kristine Salmina; Anda Huna; Thomas R Jackson; Alejandro Vazquez-Martin; Mark S Cragg
Journal:  Oncoscience       Date:  2014-12-17

9.  Effect of X-Irradiation at Different Stages in the Cell Cycle on Individual Cell-Based Kinetics in an Asynchronous Cell Population.

Authors:  Eri Tsuchida; Atsushi Kaida; Endrawan Pratama; Masa-Aki Ikeda; Keiji Suzuki; Kiyoshi Harada; Masahiko Miura
Journal:  PLoS One       Date:  2015-06-18       Impact factor: 3.240

Review 10.  Oncogenic cancer/testis antigens: prime candidates for immunotherapy.

Authors:  Morten F Gjerstorff; Mads H Andersen; Henrik J Ditzel
Journal:  Oncotarget       Date:  2015-06-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.